Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Harvard Scientific (HVSF)Hot$$- male impotency medicine -- Ignore unavailable to you. Want to Upgrade?

To: Timothy Grimes who wrote (2843)	1/22/1998 2:36:00 PM
From: Wally	Respond to of 3906

Timothy: All of your points are well-taken. On the potential upside of each argument: 1. The product is meaningless without a delivery system. It's like a Space Shuttle without a rocket (no puns intended). 2. There was a dramatic climb recently. ALSO with NO news. I invested in Microsoft last year. I got in at 121. That same day, they reported better the expected quarter and Greenspan gave a speech saying NO interest rates. The stock lost 10 points by the end of the day. And THIS was a stable stock. 3. I don't know. Being debentured up to their asses, I doubt that they were looking to cause further damage. I don't know where to look for proof of such an "infusion." If you have any ideas here, please let me know. I honestly appreciate your skepticism and I think this question may be the most pivotal because it will determine management's credibility. 4. As far as NASDAQ rules changes. Who knows. NASDAQ has little credibility having had their OWN scams exposed recently. I think this answer centers on timing. Both HVSF's ability to straighten out a year's worth of bad decision making and NASDAQ's potential of generosity with companies that show positive movement. 5. Money for the long haul is MY biggest concern. I agree with your characterization of the FDA approval process. In my last post I stated that winding thru the Phase II & III process is no picnic. My summation of their position is that HVSF has a potentially strong product (for both Impotency & Skin). They have a very weak organization with tremendous debt & tremendous management turnover & turmoil. If the recent reorganization is not too little too late, based on product, they have a good shot. Regards, Wally